Management of High Grade Dysplasia patients
| Cancer Alliance | National | ||
|---|---|---|---|
| Number of High Grade Dysplasia patients in audit | 37 | 1120 | |
| Cancer Alliance | National | ||
| Method of Diagnosis | |||
| – First diagnosis confirmed by second pathologist | N/A | 90.3% | 90.0% |
| Treatment planning | |||
| – HGD plan discussed at MDT | N/A | 81.1% | 93.0% |
| – Treatment plan for active treatment | N/A | 69.7% | 82.0% |
| First treatment | |||
| – Endoscopic therapy (such as endoscopic resection) | N/A | 63.6% | 78.0% |
| – Surveillance | N/A | 6.1% | 11.0% |
NOTE: Percentages have been calculated based on the number of patients with recorded data for each variable and not the total number of patients in the Cancer Alliance.
Management of oesophago-gastric cancer patients
| Organisation | National | ||
|---|---|---|---|
| Number of oesophago-gastric (OG) cancer patients in audit | 62 | 19,865 | |
| Case ascertainment for OG cancer (%) | 85-100% | ||
| Method of Diagnosis | |||
| – Patients diagnosed after an emergency admission** ** Percent figure accounts for differences in mix of patients across organisations |
26 | 34.4% | 13.1% |
| – Patients with referral source reported as unknown | 0 | 0.0% | 1.4% |
| Pre-treatment staging of cancer | |||
| – Patients having staging CT scan recorded | N/A | 94.0% | |
| Treatment planning | |||
| – Patients having a plan for curative treatment | 20 | 32.3% | 37.2% |
| – Patients having a plan for non-curative treatment | 42 | 67.7% | 62.8% |
| – Patients with non-curative plans having chemotherapy or radiotherapy | 16 | 38.1% | 34.7% |